Ignyta announces phase 1 clinical trial data for Entrectinib

Nerviano, June 1, 2015 - Well tolerated, with no drug-related serious adverse events. Recommended phase 2 dose determined. 91% response rate in patients meeting expected phase 2 eligibility criteria  (see Ignyta press release).
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.